Impact of Added Fluvastatin to Standard-of-Care Treatment on Sustained Virological Response in Naïve Chronic Hepatitis C Patients Infected with Genotypes 1 and 3Selic Kurincic T. · Lesnicar G. · Poljak M. · Meglic Volkar J. · Rajter M. · Prah J. · Baklan Z. · Kotar Z. · Maticic M.
aDepartment of Infectious Diseases and Febrile Conditions, General Hospital Celje, Celje, bInstitute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, and cClinic for Infectious Diseases and Febrile Illnesses, University Medical Centre Ljubljana, Ljubljana, and dDepartment of Infectious Diseases and Febrile Illnesses, University Clinical Centre Maribor, Maribor, Slovenia
Objectives: The combination of pegylated interferon-α and ribavirin is a standard-of-care (SOC) treatment for chronic hepatitis C (CHC), and it achieves a sustained virological response (SVR) in 41-52% of genotype 1 and in 73-79% of genotype 3 patients. In a few clinical trials, the combination of fluvastatin and SOC increased the SVR in genotype 1 patients. Methods: This prospective study enrolled 179 naïve CHC patients. In the fluvastatin group patients received the combination of SOC and fluvastatin 80 mg daily; historical controls matching the study group in genotype, age and gender were treated with the SOC treatment only. Results: On-treatment viral responses as well as the SVR did not differ significantly between the two groups, except for the genotype 1 patients with a high viral load presenting a significantly higher SVR rate in the fluvastatin group (75%) compared to the control group (41%; p = 0.024). Multivariate logistic regression identified hepatitis C virus (HCV) genotype 3 infection (p < 0.001), age ≤40 years (p < 0.001), liver steatosis <5% (p < 0.01) and low viral load (p < 0.001) as independent predictors of an SVR. Conclusion: A combination of fluvastatin and SOC significantly improved the SVR in naïve CHC patients infected with HCV genotype 1 and high viral load, but it did not improve the SVR in patients infected with HCV genotype 3.
Clinic for Infectious Diseases and Febrile Illnesses
University Medical Centre Ljubljana, Japljeva ulica 2
SI-1525 Ljubljana (Slovenia)
Received: May 22, 2013
Accepted: July 16, 2013
Published online: September 26, 2013
Number of Print Pages : 8
Number of Figures : 2, Number of Tables : 2, Number of References : 37
Intervirology (International Journal of Basic and Medical Virology)
Vol. 57, No. 1, Year 2014 (Cover Date: December 2013)
Journal Editor: Manuguerra J.-C. (Paris)
ISSN: 0300-5526 (Print), eISSN: 1423-0100 (Online)
For additional information: http://www.karger.com/INT